


WuXi Biologics Successfully Passes Japan PMDA GMP Inspection Again

28 February 2025 | News

Reinforcing Global Quality Standards for Biopharmaceutical Manufacturing



WuXi Biologics, a leading global contract research, development, and manufacturing organization (CRDMO), announced that it has once again successfully passed the Good Manufacturing Practice (GMP) inspection conducted by Japan's Pharmaceuticals and Medical Devices Agency (PMDA). This milestone underscores WuXi Biologics' unwavering commitment to maintaining world-class quality and regulatory compliance in biopharmaceutical production.

The inspection covered key aspects of manufacturing, quality control, and operational excellence, reaffirming WuXi Biologics' capabilities in delivering high-quality biologics to the Japanese market. This marks another achievement in the company's ongoing efforts to uphold international regulatory standards across its global network.

WuXi Biologics remains committed to advancing biopharmaceutical manufacturing excellence and expanding its global footprint to ensure reliable, high-quality supply for clients and patients.